Securities Registration: Employee Benefit Plan (s-8)
June 11 2021 - 5:13PM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on June 11, 2021.
Registration
No. 333-_____
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
S-8
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
OncoSec
Medical Incorporated
(Exact
name of registrant as specified in its charter)
Nevada
|
|
98-0573252
|
(State
or other jurisdiction of
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
Identification
No.)
|
24
North Main Street
Pennington,
NJ 08534-2218
(Address
of Principal Executive Offices)
OncoSec
Medical Incorporated 2011 Stock Incentive Plan
(Full
title of the plan)
Daniel
J. O’Connor
Chief
Executive Officer
OncoSec
Medical Incorporated
24
North Main Street
Pennington,
NJ 08534-2218
(855)
662-6732
(Name,
address, and telephone number of agent for service)
|
With
a copy to:
Matthew
W. Mamak, Esq.
Alston
& Bird LLP
90
Park Avenue
New
York, New York 10016
(212)
210-9400
|
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer [ ]
|
|
Accelerated
filer [ ]
|
Non-accelerated
filer [X]
|
|
Smaller
reporting company [X]
|
|
|
Emerging
growth company [ ]
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
[ ]
CALCULATION
OF REGISTRATION FEE
Title of securities
to be registered
|
|
Amount to
be registered
|
|
|
proposed
maximum
offering price
per share
|
|
|
proposed
maximum
aggregate
offering price
|
|
|
Amount of
registration fee
|
|
Common Stock, $.0001 par value
|
|
|
1,250,000
|
(1)
|
|
$
|
3.85
|
(2)
|
|
$
|
4,812,500
|
(2)
|
|
$
|
525.04
|
|
(1)
|
Represents
shares of common stock, par value $0.0001 per share (the “Common Stock”), of OncoSec Medical Incorporated authorized
for issuance pursuant to the grant or exercise of awards under the Company’s 2011 Stock Incentive Plan. Pursuant to
Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement on
Form S-8 (this “Registration Statement”) shall also cover any additional securities that may be offered or issued
in connection with any stock dividend, stock split, recapitalization or other similar transaction.
|
|
|
(2)
|
Estimated
solely for the purpose of calculating the registration fee. Pursuant to Rule 457(c) and Rule 457(h) under the Securities Act,
the proposed maximum offering price per share and the proposed maximum aggregate offering price have been determined on the
basis of the average of the high and low prices of the Company’s common stock reported on the Nasdaq Capital Market
on June 7, 2021.
|
PART
I
INFORMATION
REQUIRED IN The Section 10(a) Prospectus
(a)
The documents containing the information specified in Part I of this Registration Statement will be sent or given to recipients
of the awards as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).
These documents and the documents incorporated by reference in this registration statement pursuant to Item 3 of Part II of this
form, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
(b)
Upon written or oral request, OncoSec Medical Incorporated (the “Company”) will provide, without charge, the documents incorporated
by reference in Item 3 of Part II of this Registration Statement. The documents are incorporated by reference in the Section 10(a) prospectus.
The Company will also provide, without charge, upon written or oral request, other documents required to be delivered to participants
pursuant to Rule 428(b). Requests for the above-mentioned information should be directed to Robert J. DelAversano, Principal Accounting
Officer and Controller, at 24 North Main Street, Pennington, NJ 08534-2218.
PART
II
INFORMATION
REQUIRED IN REGISTRATION STATEMENT
|
Item
3.
|
Incorporation
of Documents by Reference.
|
The
following documents filed with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) are hereby incorporated by reference into this Registration
Statement:
|
(1)
|
The
Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2020, filed
on October 28, 2020;
|
(2)
All other reports filed by the Company pursuant to Section 13(a) or 15(d) of the Exchange Act since July 31, 2020; and
(3)
All other documents subsequently filed by the Company pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act prior
to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been
sold or that deregisters all securities that remain unsold.
Any
statement contained in a document incorporated or deemed incorporated herein by reference shall be deemed to be modified or superseded
for the purpose of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document
which also is, or is deemed to be, incorporated herein by reference modifies or supersedes such statement. Any such statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
Statement.
|
Item
4.
|
Description
of Securities.
|
Not
applicable.
|
Item
5.
|
Interests
of Named Experts and Counsel.
|
None.
|
Item
6.
|
Indemnification
of Directors and Officers.
|
The
Nevada Revised Statutes provide the Company with the power to indemnify any of its directors and officers. To be eligible for
such indemnification, the director or officer must have conducted himself/herself in good faith and reasonably believe that his/her
conduct was in, or not opposed to, the Company’s best interests. In a criminal action, the director or officer must not
have had reasonable cause to believe his/her conduct was unlawful.
Under
applicable sections of the Nevada Revised Statutes, advances for expenses may be made by agreement if the director or officer
affirms in writing that he/she believes that he/she has met the standards and will personally repay the expenses if it is determined
the director or officer did not meet the standards.
The
Company’s Bylaws include an indemnification provision under which the Company must indemnify any of its directors or officers,
or any of its former directors or officers, to the full extent permitted by law.
At
present, there is no pending litigation or proceeding involving any of the Company’s directors or officers for which indemnification
by the Company is sought, nor is the Company aware of any threatened litigation that is likely to result in claims for indemnification.
The Company also maintains insurance policies that indemnify its directors and officers against various liabilities, including
liabilities arising under the Securities Act, which may be incurred by any director or officer in his or her capacity as such.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted for directors, officers or persons controlling
the Company pursuant to the foregoing provisions, or otherwise, the Company has been informed that in the opinion of the Commission
such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
|
Item
7.
|
Exemption
from Registration Claimed.
|
Not
applicable.
Except
as indicated below as being incorporated by reference to another filing with the Commission by the Company, the following exhibits
to this registration statement are being filed herewith:
(a)
The undersigned Company hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most
recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
set forth in this Registration Statement;
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement
or any material change to such information in this Registration Statement;
provided,
however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the registration statement is on Form S-3, Form S-8,
or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic
reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Securities Exchange
Act of 1934 that are incorporated by reference in this Registration Statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
(b)
The undersigned Company hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each
filing of the Company’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934
(and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities
Exchange Act of 1934) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and
controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the
opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred
or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
(signatures
on following page)
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Pennington, State of New Jersey, on June 11, 2021.
|
OncoSec
Medical Incorporated
|
|
|
|
|
By:
|
/s/
Daniel J. O’Connor
|
|
Daniel
J. O’Connor
|
|
President
and Chief Executive Officer
|
POWER
OF ATTORNEY
Each
person whose signature appears below constitutes and appoints Daniel J. O’Connor and Robert J. DelAversano, and each of
them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her
and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments)
to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority
to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he
or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of their
substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
Daniel J. O’Connor
|
|
President and Chief Executive Officer (Principal Executive
|
|
June 11, 2021
|
Daniel J. O’Connor
|
|
Officer) and Director
|
|
|
|
|
|
|
|
/s/
Robert J. DelAversano
|
|
Principal Accounting Officer and Controller (Principal
|
|
June 11, 2021
|
Robert J. DelAversano
|
|
Financial Officer)
|
|
|
|
|
|
|
|
/s/ Margaret
Dalesandro, Ph.D.
|
|
Chair of the Board of Directors
|
|
June 11, 2021
|
Margaret Dalesandro, Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/ Dr.
James M. DeMesa, M.D.
|
|
Director
|
|
June 11, 2021
|
Dr. James M. DeMesa, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Joon
Kim
|
|
Director
|
|
June 11, 2021
|
Joon Kim
|
|
|
|
|
|
|
|
|
|
/s/
Dr. Herbert Kim Lyerly, M.D.
|
|
Director
|
|
June 11, 2021
|
Dr. Herbert Kim Lyerly, M.D.
|
|
|
|
|
|
|
|
|
|
/s/
Kevin R. Smith
|
|
Director
|
|
June 11, 2021
|
Kevin R. Smith
|
|
|
|
|
|
|
|
|
|
/s/ Robert
E. Ward
|
|
Director
|
|
June 11, 2021
|
Robert E. Ward
|
|
|
|
|
|
|
|
|
|
/s/
Yuhang Zhao, Ph.D.
|
|
Director
|
|
June 11, 2021
|
Yuhang Zhao, Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/ Chao
Zhou
|
|
Director
|
|
June 11, 2021
|
Chao Zhou
|
|
|
|
|
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024